News | May 01, 2025
Sigachi Industries signs MoU with Respilon Group
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
Bayer expects 2025 to be the most difficult year of its turnaround
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Phytonadione Injectable Emulsion possesses the same type and degree of activity as does naturally-occurring vitamin K
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
Subscribe To Our Newsletter & Stay Updated
